Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
E Weisberg, L Catley, RD Wright, D Moreno, L Banerji… - Blood, 2007 - ashpublications.org
… of BCR-ABL + cell lines to imatinib and nilotinib results in … BCR-ABL point mutations
causing resistance to imatinib in … , the combination of imatinib and nilotinib is highly efficacious …
causing resistance to imatinib in … , the combination of imatinib and nilotinib is highly efficacious …
Nilotinib
MW Deininger - Clinical cancer research, 2008 - AACR
… In chronic myeloid leukemia (CML), the major breakthrough has occurred with the introduction
of imatinib (Gleevec), a small-molecule inhibitor of BCR-ABL, the constitutively active …
of imatinib (Gleevec), a small-molecule inhibitor of BCR-ABL, the constitutively active …
The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity
J Salih, J Hilpert, T Placke, F Grünebach… - … Journal of cancer, 2010 - Wiley Online Library
… of the potentially differing effects of the 3 BCR/ABL-inhibitors approved for CML treatment
is available. To study the direct effects of Imatinib, Nilotinib and Dasatinib on NK cell reactivity, …
is available. To study the direct effects of Imatinib, Nilotinib and Dasatinib on NK cell reactivity, …
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
A Hochhaus, G Saglio, RA Larson… - Blood, The Journal …, 2013 - ashpublications.org
… crisis were lower with nilotinib than imatinib in patients with emergent BCR-ABL mutations.
… Nilotinib has in vitro inhibitory activity against all tested imatinib-resistant mutants of BCR-ABL…
… Nilotinib has in vitro inhibitory activity against all tested imatinib-resistant mutants of BCR-ABL…
[PDF][PDF] Comparison of the efficacy of nilotinib and imatinib in the treatment of chronic myeloid leukemia
BS Zhang, YP Chen, JL Lv, Y Yang - J. Coll. Physicians Surg. Pak, 2019 - jcpsp.pk
… in the nilotinib group were lower than those in imatinib group. It indicated that nilotinib can
… In addition, the authors also found that nilotinib improved peripheral blood neutrophils and …
… In addition, the authors also found that nilotinib improved peripheral blood neutrophils and …
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets
U Rix, O Hantschel, G Dürnberger… - Blood, The Journal …, 2007 - ashpublications.org
… The cognate target of imatinib, BCR-ABL, for which we observed peptides mapping to
both the BCR-part, as well as to the ABL-part, was identified as the major imatinib interactor. …
both the BCR-part, as well as to the ABL-part, was identified as the major imatinib interactor. …
Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL
H Kantarjian, F Giles, L Wunderle… - … England Journal of …, 2006 - Mass Medical Soc
… of the activity of nilotinib in imatinib-resistant CML. We found that nilotinib has activity in
imatinib-… with mutations in the gene that encodes the ABL kinase that cause imatinib resistance. …
imatinib-… with mutations in the gene that encodes the ABL kinase that cause imatinib resistance. …
[HTML][HTML] AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E Weisberg, P Manley, J Mestan… - British journal of …, 2006 - nature.com
… Abl … nilotinib; Figure 1E), a high-affinity aminopyrimidine-based ATP-competitive inhibitor
that decreases proliferation and viability of wild-type BCR-ABL- and imatinib-resistant BCR-ABL …
that decreases proliferation and viability of wild-type BCR-ABL- and imatinib-resistant BCR-ABL …
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil… - … England Journal of …, 2010 - Mass Medical Soc
… Our findings regarding nilotinib differ from results of these studies of imatinib in several
important respects. First, nilotinib is a more potent and selective BCR-ABL inhibitor than imatinib. …
important respects. First, nilotinib is a more potent and selective BCR-ABL inhibitor than imatinib. …
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or-intolerant accelerated-phase chronic …
P Le Coutre, OG Ottmann, F Giles… - Blood, The Journal …, 2008 - ashpublications.org
… , it acts through competitive inhibition of the ATP binding site of BCR-ABL. In vitro nilotinib is
30 times more potent than imatinib against imatinib-sensitive cell lines and 3 to 7 times more …
30 times more potent than imatinib against imatinib-sensitive cell lines and 3 to 7 times more …
相关搜索
- chronic myeloid leukemia bcr abl
- bcr abl inhibitors
- amn107 nilotinib bcr abl
- bcr abl1 mutations
- tyrosine kinase inhibitor bcr abl
- leukemia cells bcr abl
- imatinib failure bcr abl mutation status
- imatinib mesylate bcr abl
- bcr abl1 imatinib resistance
- second line nilotinib bcr abl
- imatinib in patients bcr abl
- nilotinib in patients bcr abl
- bcr abl kinase domain mutations
- mutant bcr abl